Methoxy Polyethylene Glycols (mPEGs) are increasingly being applied in drug discovery and drug development to enhance the deliverability and bioavailability of the drug, and to increase the serum half-life. Today, due to advancements in chemical processes and purification techniques it is possible to produce high-quality mPEGs.
mPEGs in combination with a small molecule drug can negate the disadvantages of poor solubility, inefficient action on the target site, low presence in the bloodstream, and toxicity. When combined with a large molecule, they help increase the half-life, resident time in the blood and help prevent the immune system responses of the body from detecting the drug as an antibody.
Methoxypolyethylene Glycols (mPEGs) have a range of applications in drug discovery and development
- Dermatology Drugs – m-PEGs being hydrophobic easily penetrate the skin on application, especially in the form of a topical formulation. Their low toxicity also makes them suitable for dermatological applications.
- Highly Potent Oncology Drugs – Methoxy PEGs are used to deliver drugs in chemotherapy to increase their effectiveness. Methoxy Polyethylene nanoparticles can be loaded with the required drug to increase its stability in the body and reduce overall toxicity.
- Polypeptide Drugs – As polypeptide drugs are unstable and degrade quickly thus reducing the half-life and amount of exposure in the bloodstream. When a polypeptide drug is combined with an m-PEG, both half-life and stability increase.
- Large Molecule Drugs – Large molecule drugs degrade quickly and get cleared from the bloodstream in a short period of time. If they are bound with mPEGs they maintain their desired form, have a greater half-life, and are not recognized as anti-bodies by the immune system.
Latest Posts
Transforming Drug Discovery with Aurigene.AI
PROTACs: Research for a life without cancer
Good practices in non-clinical toxicology assessment to accelerate IND and NDA Submissions
Continuous Flow Chemistry: A Game-Changer for Pharmaceutical Production
mRNA Technology and the Brief History of New Vaccine
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Immuno Oncology - Therapies and Challenges
HPAPI Development at a Glance
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market
Add new comment